Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Barinthus Biotherapeutics plc - American Depositary Shares
(NQ:
BRNS
)
1.450
+0.005 (+0.35%)
Streaming Delayed Price
Updated: 3:55 PM EDT, Jul 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
41,458
Open
1.480
Bid (Size)
1.470 (1)
Ask (Size)
1.500 (2)
Prev. Close
1.445
Today's Range
1.390 - 1.499
52wk Range
1.210 - 5.000
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
June 21, 2024
Via
Benzinga
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
June 12, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Performance
YTD
-60.81%
-60.81%
1 Month
+9.85%
+9.85%
3 Month
-43.14%
-43.14%
6 Month
-52.15%
-52.15%
1 Year
-64.63%
-64.63%
More News
Read More
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
June 06, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Barinthus Biotherapeutics: Q4 Earnings Insights
March 20, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
June 05, 2024
Via
Benzinga
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024
May 22, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
BRNS Stock Earnings: Barinthus Biotherapeutics Beats EPS for Q1 2024
May 13, 2024
Via
InvestorPlace
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
May 13, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
May 01, 2024
Via
Benzinga
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
May 01, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
April 30, 2024
Via
Benzinga
Infection-Focused Barinthus Bio's VTP-200 Data Underwhelming: Analyst Weighs On Mixed Perspectives
April 19, 2024
Via
Benzinga
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
April 18, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
April 04, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
April 03, 2024
Via
Benzinga
BRNS Stock Earnings: Barinthus Biotherapeutics Beats EPS for Q4 2023
March 20, 2024
Via
InvestorPlace
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
March 20, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
February 19, 2024
Via
Benzinga
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
January 05, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
New partnership aims to advance vaccine against MERS coronavirus
December 21, 2023
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
November 09, 2023
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
November 09, 2023
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
November 09, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.